Ross Firestone, Hematology/Oncology Fellow at Memorial Sloan Kettering Cancer Center, shared on their X/Twitter:

”Happy to see my first research paper of fellowship is officially in press! So, of course, it’s time for my first-ever tweet discussing observations in real-world Teclistamab patients with multiple myeloma.

Teclistamab is an excellent new therapy for multiple myeloma. We saw that patients with prior BCMA therapy exposure do a bit worse clinically, but can still achieve good responses.

Interestingly, cytokine release syndrome during step-up dosing was strongly associated with a response (100% ORR in those with CRS). Early immune engagement is a key indicator of outcome.

When looking at non-responders, we saw very few patients with loss of BCMA expression, even in patients with prior exposure to BCMA-targeting therapy.

Exploratory results show that peripheral blood T cell profiles favoring CD8 effectors over Tregs were associated with response to treatment.

Lots of work still to do (stay tuned!) but these findings, along with work from other groups, show that immune status may be critical for response to bispecifics like Teclistamab.”

Source: Ross Firestone/X